3.5.BPS1 Best practice statement
In the absence of strong evidence supporting widespread adoption of treatment for…
In the absence of strong evidence supporting widespread adoption of treatment for speech problems, interventions to improve the communication skills of listeners (i.e. communication partners of speakers with ataxia) could be incorporated into care plans. These include focused attention during conversations, communicating in quiet environments, and identification of strategies to ameliorate communication breakdowns, with practice of the strategies in a supportive environment.
Part of 3.5 Dysarthria in Friedreich ataxia
References (22)
1. Gentil M. Dysarthria in Friedreich disease. Brain Lang. 1990;38(3):438-48.
2. Hiller F. A study of speech disorders in friedreich's ataxia. Arch Neurol Psychiatry. 1929;22(1):75-90.
3. Corben LA, Klopper F, Stagnitti M, Georgiou-Karistianis N, Bradshaw JL, Rance G, et al. Measuring inhibition and cognitive flexibility in Friedreich ataxia. Cerebellum. 2017;16(4):757-63.
4. Nieto A, Correia R, de Nóbrega E, Montón F, Hess S, Barroso J. Cognition in friedreich ataxia. Cerebellum. 2012;11(4):834-44.
5. Koohi N, Thomas-Black G, Giunti P, Bamiou DE. Auditory phenotypic variability in Friedreich's ataxia patients. Cerebellum. 2021;20(4):497-508.
6. Noval S, Contreras I, Sanz-Gallego I, Manrique RK, Arpa J. Ophthalmic features of Friedreich ataxia. Eye (Lond). 2012;26(2):315-20.
7. Seyer LA, Galetta K, Wilson J, Sakai R, Perlman S, Mathews K, et al. Analysis of the visual system in Friedreich ataxia. J Neurol. 2013;260(9):2362-9.
8. Hocking DR, Fielding J, Corben L A, Cremer P, Millist L, White O, et al. Ocular motor fixation deficits in Friedreich ataxia. Cerebellum. 2010;9:411-8.
9. Naeije G, Rovai A, Pandolfo M, De Tiege X. Hand dexterity and pyramidal dysfunction in Friedreich ataxia, a finger tapping study. Mov Disord Clin Pract. 2021;8(1):85-91.
10. Poole ML, Wee JS, Folker JE, Corben LA, Delatycki MB, Vogel AP. Nasality in Friedreich ataxia. Clin Linguist Phon. 2015;29(1):46-58.
11. Vogel AP, Wardrop MI, Folker JE, Synofzik M, Corben LA, Delatycki MB, et al. Voice in Friedreich ataxia. J Voice. 2017;31(2):243 e9- e19.
12. Folker J, Murdoch B, Cahill L, Delatycki M, Corben L, A. V. Dysarthria in Friedreich's Ataxia: a perceptual analysis. Folia Phoniatr Logop. 2010;62:97-103.
13. Brendel B, Synofzik M, Ackermann H, Lindig T, Scholderle T, Schols L, et al. Comparing speech characteristics in spinocerebellar ataxias type 3 and type 6 with Friedreich ataxia. J Neurol. 2015;262(1):21-6.
14. Clarke P, Black SE. Quality of life following stroke: Negotiating disability, identity, and resources. J Appl Gerontol. 2005;24(4):319-36.
15. Gibilisco P, Vogel AP. Friedreich ataxia. BMJ. 2013;347:f7062.
16. Parr S, Byng S, Gilpin S. Talking about aphasia: Living with loss of language after stroke. UK: McGraw-Hill Education; 1997.
17. Baylor C, Burns M, Eadie T, Britton D, Yorkston K. A qualitative study of interference with communicative participation across communication disorders in adults. Am J Speech Lang Pathol. 2011;20(4):269-87.
18. Vogel AP, Folker J, Poole ML. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. Cochrane Database Syst Rev. 2014(10):CD008953.
19. Lowit A, Egan A, Hadjivassiliou M. Feasibility and acceptability of Lee Silverman voice treatment in progressive ataxias. Cerebellum. 2020;19(5):701-14.
20. Vogel A, Rommel N, Synofzik M. Intensive speech rehabilitation in degenerative ataxias improves intelligibility (Abstract). Mov Disord. 2018;33(Suppl 2):S281.
21. Vogel AP, Stoll LH, Oettinger A, Rommel N, Kraus EM, Timmann D, et al. Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS. J Neurol. 2019;266(5):1260-6.
22. Yiu EM, Tai G, Peverill RE, Lee KJ, Croft KD, Mori TA, et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015;262(5):1344-53.
Disclaimer, intended use and funding
Disclaimer
The Clinical Management Guidelines for Friedreich ataxia (‘Guidelines’) are protected by copyright owned by the authors who contributed to their development or said authors’ assignees.
These Guidelines are systematically developed evidence statements incorporating data from a comprehensive literature review of the most recent studies available (up to the Guidelines submission date) and reviewed according to the Grading of Recommendations, Assessment Development and Evaluations (GRADE) framework © The Grade Working Group.
Guidelines users must seek out the most recent information that might supersede the diagnostic and treatment recommendations contained within these Guidelines and consider local variations in clinical settings, funding and resources that may impact on the implementation of the recommendations set out in these Guidelines.
The authors of these Guidelines disclaim all liability for the accuracy or completeness of the Guidelines, and disclaim all warranties, express or implied to their incorrect use.
Intended Use
These Guidelines are made available as general information only and do not constitute medical advice. These Guidelines are intended to assist qualified healthcare professionals make informed treatment decisions about the care of individuals with Friedreich ataxia. They are not intended as a sole source of guidance in managing issues related to Friedreich ataxia. Rather, they are designed to assist clinicians by providing an evidence-based framework for decision-making.
These Guidelines are not intended to replace clinical judgment and other approaches to diagnosing and managing problems associated with Friedreich ataxia which may be appropriate in specific circumstances. Ultimately, healthcare professionals must make their own treatment decisions on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge and expertise.
Guidelines users must not edit or modify the Guidelines in any way – including removing any branding, acknowledgement, authorship or copyright notice.
Funding
The authors of this document gratefully acknowledge the support of the Friedreich Ataxia Research Alliance (FARA). The views and opinions expressed in the Guidelines are solely those of the authors and do not necessarily reflect the official policy or position of FARA.